Continuous home cage monitoring of activity and sleep in mice during repeated paroxetine treatment and discontinuation.
Circadian rhythms
Home cage monitoring
Mice
Non-invasive
Paroxetine
SSRI
Sleep
Journal
Psychopharmacology
ISSN: 1432-2072
Titre abrégé: Psychopharmacology (Berl)
Pays: Germany
ID NLM: 7608025
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
27
05
2023
accepted:
27
07
2023
medline:
27
10
2023
pubmed:
16
8
2023
entrez:
16
8
2023
Statut:
ppublish
Résumé
Non-invasive home cage monitoring is emerging as a valuable tool to assess the effects of experimental interventions on mouse behaviour. A field in which these techniques may prove useful is the study of repeated selective serotonin reuptake inhibitor (SSRI) treatment and discontinuation. SSRI discontinuation syndrome is an under-researched condition that includes the emergence of sleep disturbances following treatment cessation. We used passive infrared (PIR) monitoring to investigate changes in activity, sleep, and circadian rhythms during repeated treatment with the SSRI paroxetine and its discontinuation in mice. Male mice received paroxetine (10 mg/kg/day, s.c.) for 12 days, then were swapped to saline injections for a 13 day discontinuation period and compared to mice that received saline injections throughout. Mice were continuously tracked using the Continuous Open Mouse Phenotyping of Activity and Sleep Status (COMPASS) system. Repeated paroxetine treatment reduced activity and increased behaviourally-defined sleep in the dark phase. These effects recovered to saline-control levels within 24 h of paroxetine cessation, yet there was also evidence of a lengthening of sleep bouts in the dark phase for up to a week following discontinuation. This study provides the first example of how continuous non-invasive home cage monitoring can be used to detect objective behavioural changes in activity and sleep during and after drug treatment in mice. These data suggest that effects of paroxetine administration reversed soon after its discontinuation but identified an emergent change in sleep bout duration, which could be used as a biomarker in future preclinical studies to prevent or minimise SSRI discontinuation symptoms.
Identifiants
pubmed: 37584734
doi: 10.1007/s00213-023-06442-3
pii: 10.1007/s00213-023-06442-3
pmc: PMC10593620
doi:
Substances chimiques
Paroxetine
41VRH5220H
Selective Serotonin Reuptake Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2403-2418Subventions
Organisme : Wellcome Trust
ID : 219982/Z/19/Z
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/S015817/1
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/X002357/1
Pays : United Kingdom
Informations de copyright
© 2023. The Author(s).
Références
Am J Psychiatry. 1994 Feb;151(2):289
pubmed: 8296907
J Clin Psychopharmacol. 1996 Oct;16(5):356-62
pubmed: 8889907
Int J Neuropsychopharmacol. 2007 Dec;10(6):835-8
pubmed: 17224089
J Clin Psychopharmacol. 1998 Jun;18(3):193-7
pubmed: 9617977
J Clin Psychiatry. 1993 Apr;54(4):146-9
pubmed: 8486592
Neuropharmacology. 2018 Mar 15;131:337-350
pubmed: 29274752
Neuropsychopharmacology. 1999 May;20(5):447-59
pubmed: 10192825
Br J Pharmacol. 2008 Sep;155(2):276-84
pubmed: 18552871
Proc Natl Acad Sci U S A. 1972 Jun;69(6):1583-6
pubmed: 4556464
Pharmacotherapy. 1995 Nov-Dec;15(6):778-80
pubmed: 8602387
Drug Saf. 2022 Dec;45(12):1539-1549
pubmed: 36400895
Neurotherapeutics. 2017 Oct;14(4):1120-1133
pubmed: 28653279
Int Clin Psychopharmacol. 2000 Nov;15(6):305-18
pubmed: 11110006
Psychopharmacology (Berl). 2012 Nov;224(2):313-25
pubmed: 22707231
Curr Psychiatry Rep. 2017 Aug 9;19(9):63
pubmed: 28791566
Lab Anim. 2020 Feb;54(1):99-110
pubmed: 31665969
Nat Neurosci. 2021 Sep;24(9):1210-1215
pubmed: 34341585
BMJ. 1998 Apr 11;316(7138):1105-6
pubmed: 9552943
Fed Proc. 1983 Aug;42(11):2783-9
pubmed: 6135628
Eur J Clin Pharmacol. 2005 Jun;61(4):303-7
pubmed: 15906018
Life Sci. 2008 Jun 6;82(23-24):1169-74
pubmed: 18482738
Biol Psychiatry. 2006 Nov 15;60(10):1046-52
pubmed: 16893531
Sci Rep. 2017 Apr 25;7(1):1137
pubmed: 28442777
J Neurosci. 1999 Dec 1;19(23):10494-501
pubmed: 10575045
Am J Psychiatry. 1994 Mar;151(3):450-1
pubmed: 8109661
Sleep Med Rev. 2011 Aug;15(4):269-81
pubmed: 21459634
Neuropharmacology. 2016 Sep;108:415-25
pubmed: 27150557
Brain Res. 1979 Mar 9;163(1):135-50
pubmed: 218676
Alzheimers Dement (N Y). 2018 May 24;4:215-223
pubmed: 29955664
J Biol Rhythms. 2012 Feb;27(1):48-58
pubmed: 22306973
Genes Brain Behav. 2004 Jun;3(3):167-77
pubmed: 15140012
Br J Psychiatry. 2006 Sep;189:264-72
pubmed: 16946363
Drugs. 2005;65(7):927-47
pubmed: 15892588
Am J Psychiatry. 2004 May;161(5):826-35
pubmed: 15121647
J Psychopharmacol. 2022 Jul;36(7):794-805
pubmed: 35607713
Br J Clin Pharmacol. 1996 Dec;42(6):757-63
pubmed: 8971432
J Affect Disord. 2018 Jan 15;226:132-141
pubmed: 28972930
J Psychopharmacol. 2015 Oct;29(10):1092-105
pubmed: 26174134
Prog Brain Res. 2004;145:179-96
pubmed: 14650916
BMC Med. 2013 Mar 22;11:79
pubmed: 23521808
Brain Res. 1976 Jan 23;101(3):569-75
pubmed: 1244990
Brain Res. 1990 Nov 26;534(1-2):336-9
pubmed: 2073598
J Clin Psychopharmacol. 1995 Oct;15(5):374-5
pubmed: 8830071
Chronobiol Int. 2003 Nov;20(6):989-99
pubmed: 14680139
Transl Psychiatry. 2020 Jan 23;10(1):28
pubmed: 32066704
J Neurosci Methods. 2018 Apr 15;300:26-36
pubmed: 28414048
Sleep. 1991 Oct;14(5):439-47
pubmed: 1836894
Int Clin Psychopharmacol. 2002 Sep;17(5):217-25
pubmed: 12177584
Transl Psychiatry. 2021 Nov 15;11(1):588
pubmed: 34782594
BMJ. 2014 Dec 14;349:g7641
pubmed: 25512325
Proc Natl Acad Sci U S A. 2021 Sep 28;118(39):
pubmed: 34556572
Curr Opin Insect Sci. 2017 Dec;24:51-57
pubmed: 29208223
Biology (Basel). 2019 Mar 21;8(1):
pubmed: 30901884
Neuropsychopharmacology. 2003 May;28(5):850-6
pubmed: 12637954
Eur J Pharmacol. 2000 Oct 27;407(1-2):101-7
pubmed: 11050296
Behav Brain Res. 1996 Sep;79(1-2):183-92
pubmed: 8883829
Addict Behav. 2019 Oct;97:111-121
pubmed: 30292574
Neuropsychopharmacology. 2002 Feb;26(2):246-58
pubmed: 11790520
Calcif Tissue Int. 2004 May;74(5):469-75
pubmed: 14961209
J Neurosci. 1993 Mar;13(3):1065-79
pubmed: 8441003
Synapse. 2004 Nov;54(2):111-8
pubmed: 15352136
J Sleep Res. 2009 Sep;18(3):342-8
pubmed: 19549078
Sleep. 1995 Jul;18(6):470-7
pubmed: 7481419
Eur J Pharmacol. 2000 Sep 1;403(1-2):55-65
pubmed: 10969144
J Clin Psychiatry. 1997;58 Suppl 7:17-21; discussion 22
pubmed: 9219489
J Pharmacol Exp Ther. 2010 Jan;332(1):266-73
pubmed: 19828877
Am J Psychiatry. 2018 Dec 1;175(12):1176-1184
pubmed: 30501420
Psychopharmacology (Berl). 2008 Jul;199(1):1-14
pubmed: 18470507
Int Clin Psychopharmacol. 2014 Jul;29(4):185-96
pubmed: 24424469
Sci Rep. 2021 Mar 2;11(1):4961
pubmed: 33654141
Biol Psychiatry. 2006 Oct 15;60(8):896-9
pubmed: 16631132
Biol Psychiatry. 1993 Jun 1-15;33(11-12):851-2
pubmed: 8373925
Physiol Genomics. 2007 Jan 17;28(2):232-8
pubmed: 16985007
PLoS One. 2018 Nov 12;13(11):e0206985
pubmed: 30418990
Sci Adv. 2020 Aug 12;6(33):eabb3567
pubmed: 32851175
PLoS One. 2011;6(7):e22133
pubmed: 21760962
Psychopharmacology (Berl). 1993;113(2):225-30
pubmed: 7855186
Wellcome Open Res. 2016 Nov 15;1:2
pubmed: 27976750
J Pharmacol Exp Ther. 2019 Oct;371(1):113-120
pubmed: 31308195
Hum Psychopharmacol. 2002 Jun;17 Suppl 1:S27-32
pubmed: 12404667
Eur J Pharmacol. 2000 Jun 2;397(2-3):351-7
pubmed: 10844134
Neurosci Lett. 2016 May 27;622:30-6
pubmed: 27095588
Pharmacol Biochem Behav. 2002 Oct;73(3):557-63
pubmed: 12151030
Sleep Med Rev. 2013 Oct;17(5):377-90
pubmed: 23391633
Psychother Psychosom. 2015 Feb 21;84(2):72-81
pubmed: 25721705
Handb Exp Pharmacol. 2013;(217):157-83
pubmed: 23604479
IEEE Trans Biomed Eng. 2007 Feb;54(2):225-33
pubmed: 17278579
Psychopharmacology (Berl). 2011 May;215(2):367-77
pubmed: 21191569